Reactogenicity, Safety and Immunogenicity of an Universal Influenza Vaccine Uniflu

Summary

This is a single-site, randomized, double-blind, placebo-controlled study of Uniflu in fifty four (54) volunteers 18-60 years of age with a dose escalation. All subjects will receive an intramuscular (IM) injection twice,with a 21 days interval between treatments.

Timeline

Start

2018-06-02

Primary completion

2018-12-02

Completion

2018-12-31

Drugs

Indications

No indication recorded.